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Peripheral blood mononuclear cells from 36 asymptomatic HIV-1 seropositive individuals were tested
longitudinally for in vitro T-cell proliferation and IL-2 production in response to synthetic peptides
spanning the entire gp 120 of HIV-1. At baseline, significant T-cell proliferation to pooled and individual
peptides was observed in 15 ofthe 36 donors. After 12 months, proliferative responses to peptide pools
were lost or decreased significantly in most donors. Responses appeared to fluctuate over time: at 12
months new recognition sites were detected in four of 10 donors showing T-cell proliferation at baseline,
as well as in five of 15 donors with no previous proliferative responses. IL-2 production appeared to be a
more sensitive and longer preserved parameter of T-helpter cell function: at baseline tbe majority of
donors with no T-cell proliferation produced IL-2 in response to pooled peptides. Tbis response was not
decreased significantly after 12 months. Tbe overall patterns of response to both pooled and individual
peptides were heterogeneous among donors. Multiple recognition sites were detected in both variable and
conserved regions of gpl20, but no pool or individual peptide was recognized by all responders.
Functional T-cell responses were not statistically correlated to CD4+ cell percentile and absolute
numbers.
Professor Dr A. D. M. E. Osterhaus, Department of Virology, Erasmus University Rotterdam, P.O. Box
1738, 3000 DR Rotterdam, The Netherlands
INTRODUCTION
T-helper lymphocytes are known to play a central role in the
generation of protective immunity against infectious agents
[1-4]. Although the immune mechanisms which may mediate
protection against HIV-1 are still largely unclear, increasing
evidence suggests that the generation of strong T helper-cell
responses is critical to the prevention or control of HIV-1
infection. T helper-cell responses against gpI20 have been
demonstrated in individuals exposed repeatedly to HIV-1 but
lacking serological or other evidence of HIV-1 infection [5].
Furthermore, HIV-1 infected apes, which do not seem to
develop HIV-1-reiated disease, have vigorous T helper-cell
responses towards various HIV-1 antigens [6, 7].
Among HIV-1 antigens, the envelope protein is believed to
play a major role in the induction of protective B- and T-cell
mediated immunity against the virus [8-10]. The T helper-cell
immunostimulatory properties of gpl20 have been studied in
animal models, vaccinated volunteers, and in both seroposit-
ive and seronegative donors [9, 11-211. Synthetic peptides
have been commonly used for the screening of the gpl20-
specific T helper-cell repertoire. Beside providing information
on defined T helper-cell epitopes, the use of discrete peptides
rather than whole antigens has been reported to increase the
detection level of specific responses [18, 21, 22], and to allow
discrimination between putative T-cell activating and sup-
pressive sites [22, 23]. Moreover, this approach circumvents
the problem of HIV-1 induced defects of antigen presentation
which may interfere with the in vitro analysis of T helper-cell
responses [24,25]. Although measurement of peripheral blood
mononuclear cell (PBMC) proliferation upon antigen stimu-
lation is widely used to test T helper-cell reactivity in vitro, it
has been suggested recently that the measurement of IL-2
production is a more sensitive parameter to test for exposure
to HIV-1 than T-cell proliferation [5, 15].
The authors measured T-cell proliferation and I L-2 produc-
tion of PBMC from 36 asymptomatic HlV-1 infected indi-
viduals in response to in vitro stimulation with synthetic
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peptides spanning the entire gpl 20 of HIV-1IIIB. T helper-cell
responses against several conserved and variable sites of gp 120
in HIV-I infected individuals have been described previously.
However, since most previous studies have focused on limited
numbers ofrecognition sites [11, 15. 16.19.20], to the authors'
knowledge the T helper-cell repertoire for the entire protein
has not been screened before in seropositive individuals.
Although T helper-cell responses observed in asymptomatic
HIV-1 infected individuals have been higher than in those who
have progressed to symptomatic disease [16, 18, 19], little is
known about the longevity of these responses during the
asymptomatic phase of infection. The authors' goal was to
gain further insight into the specificities and kinetics of T
helper-cell responses during the asymptomatic stage of HIV-1
infection, before severe CD4 ^ cell-count depletion and
deterioration ofthe clinical status occur. The results indicate
that the recognition of gpl20 is heterogeneous in asymptoma-
tic seropositive individuals and appears to fluctuate over time,
Furthermore, the authors showed that in HIV-I-infected
individuals IL-2 production is a more sensitive and, longer
preserved parameter of T helper-cell function than prolifera-
tive T-eell responses.
MATERIALS AND METHODS
Study group. The study included 36 HIV-1 infected individuals 24
males and 12 females), aged 22- 52 years, randomly selected from a
cohort monitored by the Utrecht University Hospital (Utrecht, The
Netherlands) between 1987 and 1991. HlV-1 infection was related to
high-risk homosexual or bisexual contacts (rt = 21), heterosexual
contacts (n= 10), or intravenous drug use (rt = 5). To be included in
the study, HIV-1-infected individuals had to have baseline circulating
CD4^ cell counts above 400 cells/;(l. and. throughout the study, had
to show no symptoms or signs of HIV-1 related disease (stage II ofthe
Centre for Disease Control (CDC), Atlanta, GA, USA, classifica-
tion). T helper-cell responses were evaluated retrospectively with
PBMC collected at a baseline visit and. depending on availability of
hlood samples, 6 and 12 months later. Responses were assessed in
nine separate experiments, each including five HIV-1 infected donors.
Nine of the 36 donors were tested twice in independent experiments.
Total leucocyte counts, as well as percentages and absolute numbers
of CD4 * cells, were determined by standard methods, PBMC from 11
HIV-seronegative healthy blood donors were used as controls.
Synthetic peptides. A panel of 45 partially overlapping synthetic
peptides (20 mers overlapping by 10 amino acids), spanning the entire
sequenceofgpl20oftheinBstrainof HIV-1. was provided by Dr H.
Holmes through the Medical Research Council's AIDS Directed
Programme (South Minims, Potters Bar, UK). Individual peptides or
nine pools (A-I) of five contiguous peptides were used for in vitro
stimulation of PBMC,
Stimulation of PBMC. PBMC were separated from heparinized
blood by density gradient centrifugation on Ficoll-Hypaque
(Nycomed Pharma AS. Oslo. Norway), washed three times in RPMI
1640 containing penicillin (100 U/ml), streptomycin (100 /ig/ml). 10 "
M ^ -mercapto ethanol and 2 mM L- glutamine (referred to as 'complete
medium"), and cryopreserved in liquid nitrogen until use. Cell
viability (as assessed by trypan blue exclusion) was preserved after
thawing. PBMC (1.5 x lOVwelt) were cultured in triplicate in flat
bottomed 96-weli microtitre plates (Greiner, Frickenhausen, Ger-
many) in a iinal volume of 150 ;il of complete medium supplemented
with 10% heat inactivated human serum pooled from seronegative
donors. Cells were stimulated with either pooled or individual
peptides. at a final concentration of 10 /ig/ml of each peptide.
Phytohaemoagglutinin (PHA-M, Boehringer Mannheim. Mann-
heim, Germany) at a final concentration of 10 /ig/ml, was used to test
lymphocyte responsiveness to non-specific stimulation. Unstimulated
cultures (cells in medium supplemented with 10% human serum) were
used as medium control.
T helper-cell assays. For T-cell proliferation. PBMC were incu-
bated for 6 days at 37^C in a 5% CO: humidified atmosphere, pulsed
for 18 h with 0.5 /iCi of ('H)-thymidine. and harvested on glass-fibre
filter papers. (•'H)-thymidine incorporation was measured in a liquid
scintillation /(-spectrometer. For measurement of IL-2 production.
PBMC were cultured as outlined above in the presence of an anti-IL-2
receptor monoclonal antibody (MoAb) (kindly provided by Dr L,
Aarden. CLB. Amsterdam. The Netherlands), at 1:500 final dilution,
to prevent IL-2 consumption [15]. Supernatants were harvested 7
days later and frozen at — 20 C until use. IL-2level wasdefmedas the
ability to stimulate the proliferation of the IL-2-dependent cell line
CTLL-2, For this purpose, 2 days after the last feeding. CTLL celts
(0,5 X lO'* cells/well) were cultured in round bottomed 96-well micro-
titre plates, in complete medium supplemented with 10'Vi> heat
inactivated fetal calf serum (FCS). Supernatants from PBMC
cultures were added to the wells at 50 /jl/weli (dilution 1:2), Following
a 24-h incubation at 37 C, CTLL proliferation was determined by
measuring overnight incorporation of (^H)-thymidine, as described
above. CTLL cells were maintained in 25-cm- flasks (Becton
Dickinson, UK) in 10 ml of complete medium supplemented with
lO'/n FCS and 10 U/ml recombinant IL-2 (rIL-2, Biotest Diagnostics,
Dreieich. Germany).
Results of PBMC and CTLL proliferation assays are given as
stimulation indices (SI) according to tbe following formula:
SI = mean counts per min in stimulated cultures
mean counts per min in medium control cultures
Standard error of mean values was consistently below 27%.
Statistical analysis. Proliferative responses and IL-2 production
measurements with PBMC from 11 HIV-1 seronegative blood donors
showed a (one-sided) 99% upper confidence limit from the t-
distribution of 2,87 and 2,98. respectively. Based on this observation,
SI from HIV-1 seropositive donors were considered significant when
scoring ^3.0. Linear regression analysis was performed to evaluate
the relationship between T helper-cell responses and absolute
numbers and percentages of circulating CD4''' cells.
RESULTS
Proliferative responses to gpl20 peptide pools at baseline
Baseline proliferative responses of PBMC from 36 HIV-I
seropositive donors stimulated in vitro with nine pools (A-!)
of five contiguous peptides are shown in Table 1 (left panel).
Significant T-eell proliferation to at least one peptide pool was
detected in 15 of the 36 donors (42%; referred to as
•responders"), whereas 21 donors (referred to as 'non-res-
ponders') did not show significant proliferative responses. The
mean number of pools recognized by all responders was
2.9+1.1. Ten ofthe 15 responders recognized three or more
pools. Positive SI values ranged up to 14.3 (mean 5.1 ±2.7).
r Helper-Cell Responses to HIV-I gpl20 357
Table 1. Proliferative responses of PB]MC from HIV-1 seropositive donors to peptide pools A to I. (bold: SI ^ 3,0).
Donor
1*
2
.1
4* i
5
6
7
S* ]
9
]0
It
12
13*
]4
15
16
17
18
19
20 :
21* (
22*
23 {
24
25 :
26
27
28 (
29
30 (
31*
32*
33
34
35
1(>* (
A
.7
!>.6
.5
5.3
.9
1.2
.1
1.8
t.O
.6
.7
r.3
.4
.9
.5
.0
.8
.8
.0
>.3
).9
.7
).8
.6
-.2
.7
.1
).8
.0
).7
.6
.1
.4
.0
.t
.9
B
Ll
1.2
3.0
0.9 *
3.6 .
6.1
9.0
4.8
1.3
2.1
I.I
1.7
1.7 (
1,2
1.4 .
0.9 (
0.8
1.3
1.1
0.9
0.6
1.3
0,8
0.9
1.5
1.9
0.5
2.1
C
2.2
).9
1.2
1.0
i.2
).4
.8
J.3
.7
2.3
.2
.1
).6
l\
U
).9
.0
.0
.0
.0
.5
.2
.2
.0
.2
.9
.0
.3
0.7 0.8 (
0.9
0.8 (
1.4
1.2
0.7
0.4
.5 (
).7
.5
.6
.2
.3
l.l 0.7
D
1.2
3.6
1.8
3.9
.2
1.0
3.6
1.3
1.7
2.5
3.9
.4
3.9
5.3
1.9
.0
.7
.2 (
).5
.1
.8
1.2
.2
.1
1.4
.8
.0
.0 {
).5
).7
.0 :
.2
.1 :
.4
.0
.3
baseline
E
3.8
.7
.7
1.4
J.7
3.6
2.3
.6
J.2
.9
1.2
i.2
),8
>.7
>.9
.5
M
).8
.7
.1
.5
.8
.4
.5
.2
.7
.4
).8
.1
.7
..5
.0
..7
.6
.1
.5
F
5.4
1.1
2.0
0.5
0.9
1.3
4.3
1.8
1.0
3.6
1.1
0.8
4.1
1.7
1.2
0.8
1.3
1.2
1.0
i.l
2.2
1.3
1.5
0.9
1.9
1.9
0.8
1.6
1,1
0,6
0,8
0.7
2.8
0.9
0.5
1.3
G
5.4
2.4
1.7
0.9
3.1
14.3
2.4
2.0
3.0
2.9
3.2
2.0
1.1
2.4
1.4
0.8 (
0.9
1,2 {
1.2
1,0
0.8
2.3
1.2
1.2
2.1
1.6
0.7 (
1.5
1.4 (
1.0
H
.0
5.8
.0
3.7
.2
3.7
.3
.3
.2
5.2
.2
).9
).5
.1
.8
3.9
.0
3.4
.4
.0
.2
.9
.4
,4
1.2
,6
).8
.5
).9
.0
0.8 0.8
1.1
2.0
0.7
.3
.7
.0
1.1 0.8
1.0 ().8
I
8.2
2.0
6.4
4.6
1,6
14.1
1.2
1.4
1,0
3.6
3.4
2.4
0.7
1.2
1.8
1.2
1.0
1,6
0,9
1.0
0,9
2.3
1.4
1.0
1.8
2.2
1.0
1.8
1.6
0.6
1,2
2,1
1.5
1,5
2.6
1.0
A
2.0
3.2
1.3
i.O
1.4
7.5
1,5
1,4
1,0
1.8
1.4
0.7
2.8
I.I
1.1
1.4
0.7
2.0
2,3
1.7
0.8
0.8
4.1
1.1
4.1
B
1,9
2.1
1.2
1.7
1.8
6.8
0.9
0,9
1.8
2.7
1,0
1.1
1.9
0.9
i.l
1.2
0.5
0.9
1.0
1.3
0.9
1.0
1.2
1,0
1.2
C
5.4
1,1
1.6
3.9
1.2
2.2
I.I
0,9
1,0
2.2
1.0
0.8
2.5
1.3
1.2
1.5
0.6
5.4
1,3
1,2
2.4
0.6
1.2
0,7
1.2
D
2,8
0,7
1,2
1.4
1.0
2.2
1.0
3.6
1,5
1.7
1.0
0.8
2.0
1.1
1.8
1.7
0.8
1.2
1,1
1.9
1.8
2.1
1.4
1.1
1.4
Baseline
E
5.8
1.2
2.8
3.4
1.3
1.6
1.9
1.3 '
1,0
2.3
1.6
1.6 (
4.2
1.0 (
I.I
1.5
1.2
1,3
1,0
1.3
1.5
1.3
1.5
3.6
1,5
F
4.1
,9
.1
.3
.0
.2
),9
(.5
3,8
.6
.9
3.9
1.9
3.8
.3
.7
,0
,4
,4
.0
..1
.3
.1
.2
,1
G
3.0
1,9
1,5
1.5
1.9
3.2
1.0
4.8
0,8
3.0
1.8
0.8
1.9
0.9
1.3
2.3
1.3
2.3
2.0
2,2
1.1
1.1
1.0
0,7
1,0
H
2.7
1,8
2,3
6.1
1.2
1.9
2.6
0.6
2.8
2,1
1.0
0.8
8.2
1.0
1.3
1.8
1.6
3.3
1.8
1.2
1.5
1,6
1.4
1.6
1.4
I
5.3
0.6
1.3
3.5
1.2
1.4
1.4
1.9
1,0
2.1
1.7
1.5
1.2
0.9
1.4
1,1
0.9
2,5
1.4
1.1
1.0
0.6
1.6
1,1
1,6
• Results are mean SI values from two independent experiments (SD < 10%).
PBMC from 11 HIV-1 seronegative healthy controls did not
proliferate to any of the peptide pools (data not shown).
Proliferative responses to gpl20 peptide pools 12 months
after baseline
Proliferative responses could be evaluated 12 months after
baseline determination with PBMC from 10 responders and
15 non-responders. As shown in Table 1 (right panel), four of
the 10 responders lost their proliferative responses (indi-
viduals 3, 5,10 and 12), whereas six retained their responses to
at least one pool of peptides. Although in most cases
proliferative responses were directed towards the same pools
recognized at baseline, new responses to previously unrecog-
nized pools were demonstrated in four responders (individuals
4, 8, 11 and 14). New reactivities were observed also with
PBMC from five of the 15 non-responders towards one
(individuals 32. 34 and 36) or two (individuals 18 and 25)
peptide pools. The mean number of pools recognized by all
donors was 2.2 ± 1.4. Positive SI values ranged up to 8.2 (mean
4.6+1.4). Patterns of pool recognition were still heteroge-
neous 12 months after baseline.
The overall response ofthe PBMC from these 25 donors to
non-specific stimulation with PHA remained intact during
these 12 months. Differences in peptide pool-specific re-
sponses did not correlate with differences in PHA-induced
responses: 18 ofthe donors showed a higher SI to PHA at 12
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Table 2. Proliferative responses to individual peptides of PBMC from 15 HIV-1 seropositive donors responding to one or more peptide pools,
Peptide
number*
Al
A2
A3
A4
A5
Bl
B2
B3
B4
B5
Cl
C2
C3
C4
C5
Dl
D2
D3
D4
D5
El
E2
E3
E4
E5
FI
F2
F3
F4
F5
Gl
G2
G3
G4
G5
HI
H2
H3
H4
H5
11
12
13
14
15
Amino-acid
sequence
30 51
42 61
52-71
62-80
72-91
81-101
92 111
102-121
112-130
122-141
131-151
142-161
152-171
162-182
172-191
182-201
192-211
202-221
212-231
222-241
232-251
242-261
252-271
262-281
272-291
292-310
302-321
311-329
322 341
330-349
342-361
350-370
362-381
380-393
392-411
402 420
412-431
421-440
432-451
441 461
452-471
462-481
472-491
482-501
492-512
Region
Number of
responders Highest SI
Mean SI olall
responders
V2
V3
V4
V5
6.3
8.7
5.3
3.5
5.4
5.9
6.0
3.1
4.6
6.5
6.7
3.3
7.4
3.6
5.5
5.0
4.3
3.4
7.4
3.2
8.3
9.9
5.6
7.6
7.8
9.1
3.2
5.8
9.3
5.7
6.3
3.5
9.8
8.2
4.9
4.6
6.6
4.3
3.5
5.1
5.9
4.4
3.1
3.9
4.3
4.4
3.3
5.4
3.6
4.2
4.8
3.9
3.4
7.4
3.1
5.0
9.9
5.6
7.6
5.5
6.0
3.2
4.4
9.3
5.7
6.3
3.5
7.2
6.0
4.9
* Individual peptides are indicated by respective pool (A-I) and by position inside the pool (1-5).
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Fig. 1. Proliferative responses to individual peptides determined at baseline, and after 6 and 12 months in eight HlV-1 seropositive
individuals. Symbols indicate individual peptides used for cell stimulation.
Table 3. IL-2 production defined as SI of CTLL proliferation to culture supernatants of PBMC from HIV-I seropositive donors stimulated
with peptide pools A-I. (bold; SI 3=3.0)
Donor
6
8*
13*
15
17
18
19
20
21*
22*
23
24
25
26
27
28
29
30
31*
32*
33
A
2.5
3.6
4.5
9.7
4.8
5.6
1.8
3.7
1.0
1.6
0.5
3.1
0.7
2.5
1.3
0.6
0.8
1.1
0.8
0.5
1.4
B
3.0
3.6
3.1
1.7
1.4
2.1
7.7
2.4
0.9
0.9
1.2
2.0
3.0
1.4
0.7
3.2
0.8
0.7
1.0
0.4
1.4
C
2.5
4.2
2.1
3.6
7.4
2.3
1.7
3.5
3.0
1.5
1.0
3.6
3.2
8.5
1.6
1.1
1.1
1.5
1.2
2.9
1.2
D
2.1
2.8
2.1
i,7
4.2
3.0
1.5
1.6
1.8
4.4
0.5
1.0
2.8
1.3
2.1
3.7
1.4
0.9
1.2
0.7
1.2
Baseline
E
3.8
2.7
5.6
2.4
3.5
4.1
2.3
3.4
3.3
9.7
4.5
I.I
0.4
1.3
4.5
I.l
I.I
1.0
2.9
0.6
1.8
F
1.6
2.1
7.5
1.6
2.4
1.8
1.5
1.7
2.2
1.2
0.8
0.6
0.7
0.9
2.1
0.9
1,4
0.9
1.9
2.5
1.3
G
3.9
1.7
4.0
3.2
1.3
2.4
15.0
2.0
1.8
2.0
0,5
0,9
1.0
2.5
2.1 :
0.6 (
0.8
H
2.0
2.8
1.2
.5
).6
.9
,1
.7
.1
.2
.5
.4
.2
.0
..6
).3
.3
0.9 0.7
1.0 ,0
0.7 0.3
1.4 .5
I
3.5
1,8
4.2
9.2
7.5
4.5
3.0
1.9
3.7
1.0
2.6
0.7
1,7
2.8
1.7
1.2
0.8
2.3
0,7
0.3
1.9
A
2.8
3.3
0,7
1.1
3.3
1.3
5.0
0.9
1.0
1.5
B
1.3
0.9
1,5
1,1
1.7
0,9
0.9
0.7
0.8
1,2
C
4.9
2.2
1.2
8.1
1.9
3.6
2.9
3.2
1.4
0.9
D
3.3
8.4
I.l
1,4
2.2
0.6
1.4
1.1
0.7
0.7
12 months
E
2.7
8.7
0.5
9.5
2.5
0.5
1.2
2.2
1,2
0.6
F
2.3
0.8
1.0
1.2
1.3
1.0
0.9
6.1
2.1
0,6
G
1,4
0.9
2.3
2.0
1.4
0.9
12.3
2,8
1,6
0.7
H
I.I
2.9
0,8
1.0
1.6
3.3
1.3
1.2
0.8
1.5
I
3.3
0.6
3.1
19.0
1,8
0.7
6.6
2.6
1.0
2.1
* Results are mean SI values of CTLL proliferation to culture supernatants obtained from two independent experiments (SD < 10%).
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months whereas of the other seven only two (individuals 12
and 34) showed a more than two-foid decrease in SI at 12
months as compared to baseline.
Mean values of (^H)-thymidine incorporation in PHA-stim-
ulated cultures were 16,064 cpm (range: 4508-32.208) at base-
line and 19,583 (range: 4374-67,073) 12 months later. Mean
values of (^H)-thymidine incorporation in medium control
cultures were 665 cpm (range: 143-1690) and 461 cpm (range:
138-1155), at baseline and 12 months later, respectively.
Kinetics of proliferative responses to individual gpl 20
peptides
PBMC from 15 seropositive donors responding to pooled
peptides were assayed for proliferative responses to the
individual peptides of the recognized pools (Table 2). Re-
sponses to at least one peptide of the respective pools were
detected in all 15 donors. Twelve donors responded to three or
more peptides representing one or more pools. Positive SI
values ranged up to 9.9 (mean 5.1 + 1.1). As was observed with
responses to pooled peptides, a broad range of recognition
was demonstrated. Multiple recognition sites were detected in
both variable and conserved regions of gpl 20, but no single
peptide was able to stimulate PBMC from all responders. Five
peptides covering amino-acid sequences 142-161. 152-171,
172-191, 272-291, and 380-393. and designated C2, C3, C5,
E5, and G4, respectively, induced responses more frequently.
Nine of the 15 responders (67%) recognized at least one of
these peptides (data not shown). As a control, proliferative
responses to the individual peptides of non-recognized pools
were measured with PBMC from six responders and four non-
responders. No proliferative responses were observed in these
assays (data not shown). The kinetics of peptide recognition at
6 and 12 months after baseline could be evaluated in eight
responders. As shown in Fig. I, most donors showed a general
decrease in reactivity after 6 months, which was more
pronounced after 12 months.
IL-2 production to gpl20 peptide pools at baseline
The authors assayed the baseline pool-induced IL-2 produc-
tion of PBMC from four responders and 17 non-responders
from whom samples could be obtained (Table 3, left panel).
PBMC from all the four responders (individuals 6, 8, 13 and
15) were shown to produce IL-2 in response to the pools that
also induced proliferation. The numbers of pools stimulating
IL-2 production were equal to (individual 8) or higher than
(individuals 6. 13 and 15) those inducing proliferative re-
sponses. Among the 17 non-responders, lL-2 production to at
least one pool of peptides was demonstrated in 12 cases (71%).
PBMC from nine of these 12 donors produced lL-2 in
response to three or more pools. The mean number of pools
recognized by all donors was 2.9 + 1.4. In the healthy control
group, stimulation with pooled peptides did not induce
significant IL-2 production (data not shown).
IL-2 production to gpl20 peptide pools 12 months after
baseline
IL-2 production in response to pooled peptides could be
evaluated 12 months after baseline determination in 10 donors
(Table 3, right panel). Among eight donors who had shown
IL-2 responses at baseline, the number of pools recognized
after 12 months remained unchanged in three cases (indi-
viduals 21, 25 and 28). increased in one case (individual 26),
and decreased in the other four cases (individuals 17, 18, 19
and 24). New reactivities to previously unrecognized pools
emerged in three ofthe eight donors (individuals 25, 26 and
28). No new reactivities emerged in the two donors who had
failed to produce IL-2 at baseline (individuals 29 and 31).
T helper-cell responses in relation to circulating CD4^ cells
Absolute numbers and percentages of circulating CD4+ cells
had baseline mean values of 786+291 cells/^l and 36 + 9.5%,
respectively. After 12 months, mean values were 656 ±262
cells/;il and 30± 10%, respectively. Linear regression analysis
demonstrated the absence of significant association between T
helper-cell responses and absolute or percentile numbers of
CD4+ cells, at baseline or 12 months later (data not shown).
Moreover, baseline CD4*^  cell parameters proved not to be
predictive for loss of T-helper responses 12 months later.
DISCUSSION
In this paper the authors have shown that T-cell proliferative
responses to partially overlapping synthetic peptides covering
the entire amino-acid sequence of gpl 20 are heterogeneous in
asymptomatic HIV-I infected individuals and decline signifi-
cantly during a 12-month observation period. As compared to
T-cell proliferation, measurement of IL-2 production upon
specific stimulation appears to be a more informative and
longer preserved parameter of T helper-cell function (Table 3).
This is in line with earlier observations by Clerici et al. [5],
suggesting that IL-2 production by T cells in response to
synthetic peptides is a more sensitive indicator of exposure to
HIV-I than the presence of serum antibody, T-cell prolifera-
tion, or PCR assessment.
Proliferative responses obtained with individual peptides
were concordant with those obtained with pools of five
contiguous peptides. This allowed the authors to economize
on the use of PBMC in in vitro assays. The patterns of response
towards both pooled and individual peptides were heteroge-
neous among donors, and multiple sites were recognized in
both variable and conserved regions of gp 120 (Table 2), This is
likely to reflect, at least in part, MHC polymorphism which is
probably high in this group of individuals who were selected
randomly from a large panel of asymptomatic seropositive
donors with CD4"^ counts above 400. A similar heterogeneous
response to synthetic pjeptides covering the entire amino-acid
sequence of SIV gpl 20 was observed recently using T-cell
clones from immunized macaques [26]. In HlV-I infected
individuals, most previous studies on T helper-ceil responses
to gpl20 synthetic peptides have focused on limited numbers
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of recognition sites [11, 15, 16, 19, 20], often predicted as
immunodominant T helper-cell epitopes on the basis of their
amphipathic a-helic structure [27]. However, in a comprehen-
sive analysis ofthe COOH-terminal of gpl20 Wahren et al.
[18] showed that, T helper-cell responses can be elicited not
only by peptides with the predicted a-helical structure, but e.g.
also by peptides with a ^ -turn configuration. Our data showed
the presence of T-helper determinants scattered throughout
gpl20 (Table 2). Comparison of these results with those
obtained in earlier reports is complicated by the fact that in
many cases lower SI threshold values have been considered
positive. The authors chose to consider positive, values above
3.0, on the basis of results obtained with PBMC from 11
seronegative donors, whose Sl-vaiue t-distribution showed a
99% upper confidence limit of 2.87 for proliferative responses,
and 2.98 for IL-2 production. It is noteworthy that prolifera-
tion to the T helper-cell epitope envT2 (amino acids 112-124)
described previously [28] was observed in three of the 15
responders, whereas none of the donors showed T-cell
proliferation to the other two T-helper epitopes envTl (amino
acids 428-443) [29] and p 18 (amino acids 315-319) [30] (Table
2). In the study described here none ofthe pooled or individual
peptides were recognized by all or most responding donors
and, consequently, no immunodominant site could be identi-
fied. The authors were able to map five recognition sites to
amino-acid sequences 142-161 (peptide C2), 152-171 (peptide
C3). 172-191 (peptide C5), 272-291 (peptide E5). and 380-393
(peptide G4), which induced blastogenic responses with higher
frequency: nine of the 15 responding donors (67%) prolifer-
ated to at least one of these five peptides (Table 2). One
possible explanation for the lack of detectable T helper-cell
responses in some of the individuals studied, could be the use
of synthetic peptides spanning the IIIB sequence of gpl20 in
donors infected with HIV-1 strains of different geographical
origin. This approach was chosen intentionally to obtain
information on the recognition of gpl20 determinants whose
immunostimulatory properties are conserved among different
viral strains and may therefore have particular relevance to
vaccine development.
Results of earlier studies indicate that individuals in the
advanced stage of HIV-I infection have weaker antigen-
specific T helper-cell responses than asymptomatic individuals
[16, 18, 19]. Moreover, a sequential loss of T helper-cell
reactivity, to recall first antigens and then alloantigens and
mitogens, has been described in HIV-1 infected individuals by
Ckrici et al. [31]. The authors" goal in the study described here
was to evaluate the kinetics of the gpl20-specific T-helper
responses in the early phase of infection, before severe
depletion of CD4+ cell and development of HIV-1-related
disease occured. One interesting aspect in the longitudinal
evaluation ofboth T-cell proliferation and IL-2 production to
pooled peptides was the emergence, after 12 months, of new
reactivities not detected at baseline, which in several cases
compensated for the loss of determinants recognized pre-
viously (Tables I and 3). A fluctuation of gpl20-specific T
helper-cell responses over time was suggested also by the
kinetics of responses to individual peptides. In three of the
eight donors studied (individuals 2, 4 and 11), proliferative
responses to individual peptides were lost after 6 or 12 months,
whereas those to the respective pools were still detectable.
Although the identification of the new sites of recognition
might have brought interesting information, lack of cell
samples prevented further investigation.
In the authors' study T helper-cell functional responses
were shown not to be correlated to absolute or percentual
numbers of circulating CD4+ cells, both at baseline and 12
months later. Moreover, baseline CD4+ cell parameters were
not found to be predictive for the persistence or loss of T
helper-cell responsiveness 12 months later. This is not surpris-
ing in view of earlier observations that the T helper-cell
functionality of seropositive individuals is affected very early
in the course of HIV-1 infection and may be predictive for the
onset of decline in CD4^ cell numbers, rather than a
consequence of such decline [31-35].
The authors' cohort of 36 seropositive individuals remained
asymptomatic throughout the study. Subsequent clinical
follow-up showed that all donors remained asymptomatic up
to 24 months after the baseline visit. The only exception was
individual 24, who showed no specific proliferative responses
and low levels of IL-2 production both at baseline and 12
months later, and has in the meantime progressed to sympto-
matic disease (CDCIV-Cl).
Collectively, the authors' results suggest that a progressive
deterioration of HIV-I-specific T helper-ceil function occurs
during the early stage of HI V-1 infection. The antigen-specific
T-cell proliferation declines first, whereas the ability to
produce IL-2 upon specific stimulation is preserved for longer.
This tendency towards progressive decline appears to develop
with a fluctuating pattern, so that the loss of reactivities is
comf>ensated initially for by the emergence of newly acquired
recognition sites. Further prospective evaluation of the cohort
studied, may reveal a possible relationship between the gp120-
specific T helper-cell function and progression of HIV-I-
related disease.
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